The 50 most recent market catalysts affecting $MRK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Bullish
Impact 55
Bernstein Research Adjusts Price Target for Merck KGaA
Bernstein Research has raised its price target for Merck KGaA from €151 to €178, indicating a more optimistic valuation for the company. This change, while maintaining a 'Market-Pe…
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 55
Merck Expands Clinical Operations Hub in Athens
Merck KGaA is expanding its clinical operations in Athens, designating it as a strategic hub for data infrastructure and digital innovation. This move is significant as it indicate…
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 65
Merck Receives Positive EU CHMP Opinions for ENFLONSIA and WELIREG
Merck announced that the EU's CHMP adopted positive opinions for two of its drugs, ENFLONSIA and WELIREG. This is a crucial regulatory milestone, as CHMP opinions often lead to fin…
Nov 13, 2026
Corporate Catalyst
Bullish
Impact 65
Merck Receives Positive EU CHMP Opinion for ENFLONSIA® (clesrovimab) Expansion
The filing announces that the European Medicines Agency's CHMP has recommended expanding the approval for Merck's ENFLONSIA® to include a broader population of high-risk infants fo…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 65
Merck KGaA Confirms Planned Acquisition of Bio-Techne
Moody's affirmation of Merck KGaA's 'A3' credit rating with a stable outlook, despite significant acquisition plans, signals confidence in the company's financial discipline and op…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 55
Moody's Confirms Merck KGaA's 'A3' Rating Amid Planned Acquisitions
Moody's has reaffirmed Merck KGaA's 'A3' long-term credit rating with a stable outlook, a significant development as it explicitly incorporates the planned acquisitions of Bio-Tech…
Nov 11, 2026
Corporate Catalyst
Bullish
Impact 55
Moody's Affirms Merck KGaA's 'A3' Long-Term Rating
Moody's has affirmed Merck KGaA's 'A3' long-term credit rating, maintaining a stable outlook. This decision is based on the company's consistent operating performance across its bu…
Nov 10, 2026
Corporate Catalyst
Bullish
Impact 65
FDA Approves Merck's PIMJETMI (pimicotinib) for Tenosynovial Giant Cell Tumor
Merck KGaA received FDA approval for PIMJETMI, a treatment for tenosynovial giant cell tumor. This is significant as it expands the company's rare disease drug portfolio, following…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 75
Merck Announces Positive Phase 2b Results for Efinopegdutide in MASH Treatment
Merck announced positive Phase 2b results for efinopegdutide, a GLP-1/glucagon receptor co-agonist, in treating MASH with F2/F3 liver fibrosis. This is a significant development as…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 75
Eisai and Merck Receive Complete Response Letter for LENVIMA and KEYTRUDA Combination
Merck and Eisai announced they received a Complete Response Letter (CRL) for their LENVIMA and KEYTRUDA combination therapy for first-line unresectable hepatocellular carcinoma. A …
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 65
Merck Healthcare and JD Health Announce Strategic Partnership
Merck Healthcare and JD Health have signed a three-year strategic cooperation agreement, designating JD Health as the preferred online platform for Merck's new drug launches in Chi…
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 55
Merck Deepens Strategic Partnership with JD Health to Expand Access to Innovative Medicines in China
Merck is deepening its strategic partnership with JD Health to enhance patient access to its innovative medicines in China. This collaboration is significant because it utilizes JD…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 92
Merck & Co., Inc. Reports Third-Quarter 2026 Financial Results
Merck & Co. announced its Q3 2026 financial results, showing a 4.7% increase in total sales to $18.09 billion, but a 12.4% decline in net income and EPS. This mixed performance, co…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 75
Merck Updates 2026 Financial Guidance
Merck & Co., Inc. has revised its 2026 financial outlook upwards, increasing its worldwide sales guidance by $500 million at the lower end and its non-GAAP EPS guidance by $0.11 at…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 55
FDA Grants Emergency Use Authorization for Merck's Bravecto
Merck's Bravecto, already approved for flea and tick prevention, has received Emergency Use Authorization (EUA) from the FDA for new screwworm infestations in dogs. This is a posit…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 65
Merck Initiates Phase 3 ENHANCE-3 Clinical Trial for OHTUVAYRE in COPD Patients
Merck announced the commencement of its ENHANCE-3 Phase 3 clinical trial for OHTUVAYRE (ensifentrine), targeting the prevention of COPD exacerbations in adult patients already on s…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 55
Merck to Present New Data from Its Oral HIV Portfolio at HIV Glasgow 2026
Merck is set to present new clinical data from its oral HIV portfolio, specifically focusing on Phase 3 subgroup analyses and patient-reported outcomes for its investigational once…
Oct 30, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Trims Price Target on Merck to $140
RBC has trimmed its price target for Merck (MRK) shares from $145 to $140, while maintaining a 'Sector Perform' rating. This action suggests that RBC sees less upside potential for…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
Goldman Sachs Adjusts Price Target on Merck & Co. to $165 From $155
Goldman Sachs has raised its price target for Merck & Co. from $155 to $165, indicating an improved valuation perspective from the investment bank. This matters because a higher pr…
Oct 29, 2026
Corporate Catalyst
Bullish
Impact 55
Merck Opens New Asia-Pacific Bioprocessing Production Center in South Korea
Merck's inauguration of a new €300 million bioprocessing production center in South Korea signifies a strategic expansion of its manufacturing capabilities in the Asia-Pacific regi…
Oct 28, 2026
Corporate Catalyst
Bearish
Impact 85
Merck & Co., Inc. Reports Q3 2026 Financial Results
Merck & Co., Inc. reported a non-GAAP loss per share of $0.13, which was better than analyst expectations. However, this loss was largely due to a substantial $2.31 per-share charg…
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 55
HKSTP Partners with Merck to Advance Innovation and Technology
The Hong Kong Science and Technology Parks Corporation (HKSTP) has announced a strategic partnership with Merck, a major science and technology company. This collaboration aims to …
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 85
Merck and Kelun Report Positive Phase 3 Results for Sac-TMT and Keytruda Combination in NSCLC
Merck and Kelun-Biotech reported highly positive Phase 3 results for their sac-TMT and Keytruda combination in advanced NSCLC, significantly outperforming the control arm. This is …
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 65
Merck KGaA Announces Two-Year Follow-Up Results for Pimicotinib in TGCT Patients
Merck KGaA released two-year follow-up data for pimicotinib in Tenosynovial Giant Cell Tumor (TGCT) patients, showing sustained improvements in symptoms and joint function, robust …
Oct 26, 2026
Corporate Catalyst
Bullish
Impact 55
Merck Expands Innovation Presence in China's Greater Bay Area
Merck has announced a strategic expansion into China's Greater Bay Area, establishing new facilities in Shenzhen and Hong Kong. This move is significant as it positions Merck to ta…
Oct 25, 2026
Corporate Catalyst
Bullish
Impact 75
New Clinical Data Presented for KEYTRUDA in Combination with Olomorasib
Merck and Eli Lilly presented updated positive Phase 1/2 and Phase 3 clinical trial data for their combination therapy (KEYTRUDA + olomorasib) in first-line KRAS G12C-mutant NSCLC …
Oct 25, 2026
Corporate Catalyst
Bullish
Impact 75
MSD and Kelun-Biotech Announce Regulatory Progress for sac-TMT in China
MSD (Merck & Co., Inc.) and Kelun-Biotech announced that China's National Medical Products Administration (NMPA) has accepted two new indication applications for sac-TMT for priori…
Oct 24, 2026
Corporate Catalyst
Neutral
Impact 65
Bronstein, Gewirtz & Grossman, LLC Announces Investigation into Merck & Co., Inc.
Bronstein, Gewirtz & Grossman, LLC announced an investigation into Merck & Co., Inc. due to the premature release of positive Phase 3 clinical trial data for an mRNA cancer vaccine…
Oct 22, 2026
Corporate Catalyst
Bearish
Impact 75
Moderna and Merck Shares Decline Following Reports of Potential Data Leak for Melanoma Vaccine
Merck and Moderna experienced a share price decline following reports of a potential data leak regarding their experimental therapeutic cancer vaccine. This matters because the lea…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 55
Merck Collaborates with Microsoft, NVIDIA, and Dawn Health on Patient Support Programs
Merck has partnered with Microsoft, NVIDIA, and Dawn Health to innovate patient support programs for rare tumor patients. This collaboration is significant as it signals Merck's st…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 55
Merck KGaA Collaborates with Nvidia, Microsoft, and Dawn Health on AI-Driven Patient Support
Merck KGaA has announced a strategic partnership with Nvidia, Microsoft, and Dawn Health to develop an AI-driven support model for individuals with rare tumors. This collaboration …
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
Merck Announces Collaboration with NVIDIA, Microsoft, and Dawn Health
Merck has announced a collaboration with NVIDIA, Microsoft, and Dawn Health to create a digital support model for rare tumor patients. This partnership is significant as it leverag…
Oct 21, 2026
Corporate Catalyst
Bullish
Impact 65
Merck Receives European Commission Approval For KEYTRUDA In Combination With Padcev For Adults With Resectable Muscle-Invasive Bladder Cancer
Merck has secured European Commission approval for its KEYTRUDA and Padcev combination therapy for resectable muscle-invasive bladder cancer. This is a significant development as i…
Oct 20, 2026
Corporate Catalyst
Bearish
Impact 55
Merck Discontinues Bacterial Infection Drug in Europe
Merck is discontinuing Zinplava, a drug for Clostridium difficile infection, in both Europe and the United States. The European Commission formally withdrew its marketing authoriza…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 65
FDA Approves Immunotherapy That May Allow Certain Patients With Rectal Cancer To Avoid Chemotherapy, Radiation And Surgery
The FDA has approved an immunotherapy treatment for certain rectal cancer patients, which may allow them to avoid traditional treatments like chemotherapy, radiation, and surgery. …
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 85
Merck To Present First-Time Results From Three Pivotal Clinical Trials At ESMO Congress; Data Demonstrate Improvements In Recurrence-Free Survival And Distant Metastasis-Free Survival Versus KEYTRUDA Alone In Patients With Completely Resected Stage IIB-IV Melanoma
Merck is announcing that it will present first-time results from three pivotal Phase 3 clinical trials at the ESMO Congress 2026. These trials involve intismeran in combination wit…
Oct 12, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority
Merck reported positive results for its novel biologic, Remigromig, in a Phase 3 trial for diabetic macular edema (DME). The drug met its primary endpoint of non-inferiority in vis…
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165
JP Morgan analyst Chris Schott has maintained an 'Overweight' rating on Merck & Co (MRK) and raised the price target from $150 to $165. This action signals continued confidence fro…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 75
Merck Says Investigational Skin Therapy Shows Potential
Merck's announcement of positive Phase 2b results for tulisokibart in treating hidradenitis suppurativa is a significant corporate catalyst. The drug showed strong efficacy, outper…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 85
Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16
Merck announced that its investigational drug, tulisokibart, met its primary endpoint in a Phase 2b trial for hidradenitis suppurativa (HS), showing superior efficacy over placebo.…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 55
Scotiabank Maintains Sector Outperform on Merck & Co, Raises Price Target to $180
Scotiabank analyst Louise Chen has maintained a 'Sector Outperform' rating on Merck & Co (MRK) and raised the price target from $155 to $180. This action signals continued confiden…
Sep 28, 2026
Corporate Catalyst
Bearish
Impact 75
Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug
Merck and Daiichi Sankyo have pulled their FDA application for ifinatamab deruxtecan, a lung cancer treatment, due to insufficient data for accelerated approval. This is a signific…
Sep 28, 2026
Corporate Catalyst
Bullish
Impact 55
Merck's CAPVAXIVE Added To Ontario's Publicly Funded Adult Immunization Program
Merck's CAPVAXIVE vaccine has been added to Ontario's publicly funded adult immunization program, a significant development for the company. This inclusion means that eligible olde…
Sep 28, 2026
Corporate Catalyst
Bullish
Impact 75
Merck Signs Exclusive Global License Agreement With SciBrunch Therapeutics For SPR2015, An Investigational Preclinical Oral KRAS G12D Inhibitor, For $400M Up Front Plus Payments; Company To Record Pre-Tax Charge Of $0.13 Per Share In Q3
Merck has secured exclusive global rights to SPR2015, a preclinical KRAS G12D inhibitor, from SciBrunch Therapeutics. This is a significant strategic move for Merck, as KRAS inhibi…
Sep 25, 2026
Corporate Catalyst
Bearish
Impact 75
Merck, Daiichi Sankyo Voluntarily Withdraw Biologics License Application Approval In U.S. For Ifinatamab Deruxtecan To Treat Small Cell Lung Cancer After Discussions With FDA
Merck and Daiichi Sankyo have withdrawn their Biologics License Application for ifinatamab deruxtecan (I-DXd) for extensive-stage small cell lung cancer in the U.S. The withdrawal …
Sep 25, 2026
Corporate Catalyst
Bullish
Impact 75
Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component
Merck (MRK) has received FDA approval for its WELIREG plus LENVIMA combination therapy for advanced renal cell carcinoma (kidney cancer) in patients previously treated with PD-1/PD…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.